ESMO: Bristol Myers' Opdivo chalks up bladder cancer win. But a rival combo casts long shadow

Bladder cancer hasn’t been the easiest tumor type to tackle for immunotherapies. Bristol Myers Squibb has found success here with its Opdivo, but the win was overshadowed by competitor data.